- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Juliette Petit: How Nurses Can Prevent Nocebo Effect in Biosimilar Switching
Juliette Petit, MD, a French rheumatologist, talks about her recent study showing that nurses can help curb patient fears and prevent a possible nocebo effect when switching them to a biosimilar.
If you are aware of the placebo effect, you may have heard of its opposite relative, the nocebo effect, where instead of positive thinking leading to an improvement in health, patient fears about drug quality may result in little or no effect from therapy. The nocebo effect is a common concern in the biosimilar space, where patients often doubt whether biosimilars are clinically similar to reference products.
A recent study on the nocebo effect in biosimilar use demonstrated that nurses may be best able to boost patient confidence in biosimilars and improve retention rates. The authors noted that because nurses are usually the first point of contact for patients in the health care system, they can be effective advocates at facilitating switching and biosimilar acceptance.
We sat down with Juliette Petit, MD, a rheumatologist at Saint-Antoine Hospital at Sorbonne University in Paris, France, and one of the study’s co-authors to discuss some of the major points in her study what it could mean for the future of biosimilar uptake.
Learn more about Dr Petit’s study.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
